Sangamo BioScience’s CEO Elected Chairman for Advocacy Organization
Washington, D.C.-based advocacy organization, Alliance for Regenerative Medicine (ARM), elected Sangamo BioSciences’ President and CEO Edward Lanphier to serve as Chairman. ARM’s mission is to advance regenerative medicine and develop safe and effective gene and cell therapies by representing and supporting industry, clinical institutions, patient advocates and other stakeholders. Lanphier has more than 30 years experience in the pharma and biotech industries working for companies such as Somatix Therapy, BioGrowth, Synergen Inc. and Eli Lilly. Immediately following his appointment as Chairman, Lanphier briefed congressional leaders on the latest advances in regenerative medicine, presenting, “Promise and Potential: Meeting Unmet Medical Needs through Regenerative Medicine” on November 21, 2014.
Strategy Veteran to Lead PHCG’s Global Business Development
One of the largest healthcare communications companies, Publicis Healthcare Communications Group (PHCG) has named Rick Keefer as the new Global Chief Business Development Officer. Prior to this role, Keefer served as President and CEO of Publicis Touchpoint Solutions. Under his leadership as President and CEO for over eight years, the agency experienced a 10-fold growth increase. Before joining Publicis Touchpoint, Keefer held senior roles in commercial operations and sales at Biovail Corp., Pharmacia and Wyeth. In his new role, Keefer will bring his growth strategy, sales and marketing experience to bare to lead global business development for the entire network of PHCG agencies.
Mary Lupo, MD, FAAD joined the company’s U.S. Scientific Advisory Board. Lupo is a board-certified dermatologist known for her expertise in non-surgical skin rejuvenation. She served as a Botox Cosmetic trainer in 2002 and was involved in the FDA approval of Botox for the treatment of crow’s feet in 2004. Back in 1984, she opened the Lupo Center for Aesthetic and General Dermatology where she pioneered the concept of combined therapies such as neuromodulation.
A cannabis formulation-based drug development company appointed Co-founder Raymond Dabney as Director, President and CEO. Dr. Dorothy Bray, Founder, President and CEO of ImmunoClin will serve as Scientific Advisory Board Chair and Clinical Development Consultant and will work closely on a joint research project between Cannabis Science and Unistraw Holdings Pce Ltd.
Appointed Marci Piasecki as President. Leveraging her 25 years of experience working with large healthcare companies such as AstraZeneca and Bristol-Myers Squibb, Piasecki will help the agency’s teams to create brand experiences and drive results for its pharma and healthcare client roster.
Has named Jeffrey Wilks as the President of its advertising businesses, which include GSW, Palio+Ignite and Navicor, among others. In this brand new role, Wilks will work to ensure that all of Inventiv’s customers can leverage the digital expertise the company offers to help them reach their target audiences.
Promoted Kunsan Kim to Senior VP, Planning. Prior to his promotion, Kim provided high-level strategic counsel to the company’s clients to help them establish long-term relationships with their customers. Before joining LehmanMillet, Kim served as Senior Planner at IW Group and McCann World Group working on the McDonald’s and Walmart brands.
The regenerative medicine company named Christopher Cashman as Executive Vice President and Chief Commercial Officer where he will contribute his expertise to the Company’s sales and marketing functions, strategic planning and all related revenue growth initiatives. Cashman previously served as President and CEO of regenerative medicine company, Sanuwave Health.
The provider of Medication Therapy Management promoted Aaron Loutsch as SVP and Chief Technology Officer. Since joining Mirixa, Loutsch has played an important role in Mirixa’s growth and achievements.
National Pharmaceutical Council
David Martin, Senior Vice President, Market Access and Commercial Services, Eisai, was elected as Chairman of the Board. He previously served on the Board as Vice Chair and Treasurer. As SVP at Eisai, Martin leads the business-to-business interactions with the company’s major segments and customers, and commercial services teams.
Welcomes Darin Lippoldt as its Chief Legal Officer. Prior to joining Neurocrine, Lippoldt served as Executive Vice President and General Counsel of Volcano Corporation, Associate General Counsel at Amylin Pharmaceuticals, and practiced corporate and securities law at two law firms: Fulbright & Jaworski LLP and Matthews and Branscomb, P.C.
The patient access and support technology company hired Sandy W. Robinson as the new Executive Vice President. She brings 25 years experience in advising life science and charitable foundation clients on patient access and designing comprehensive patient support programs, which include co-payment assistance, patient assistance programs and adherence.
Has promoted Brad Imwalle, PhD of the Medical Education team to Senior Medical Director. In his new role, he will be responsible for pioneering the development of educational content and providing strategic insights to enhance client brands.
Reckitt Benckiser Pharmaceuticals
The specialty pharma company hired Cary J. Claiborne as Chief Financial Officer. In his role, Claiborne will lead the company’s global financial and information technology operations. Prior to joining, Claiborne served as CFO of Sucampo Pharma and has held senior positions at New Generation Biofuels, Osiris Therapeutics, Constellation Energy, Home Depot Corporation and General Electric.
Appointed Michael D. Becker as Senior Vice President, Finance and Corporate Development. Becker brings more than 20 years experience as a C-level executive and Wall Street securities analyst. He most recently served as Founder and President of MDB Communications, and as President and CEO of Cytogen and AxCell Biosciences. He also brings a wealth of experience in the financial services industry.
Named Michael T. Sweeney, MD, as Senior Vice President of Clinical Development. Sweeney is a cardiologist who will oversee clinical development of the company’s RVX-208 molecule for the treatment of cardiovascular disease, diabetes and other indications. During his career, Sweeney held senior positions at Pfizer, Impax Pharma, Depomed and CV Therapeutics.